Glenmark Pharma is currently trading at Rs. 553.95, up by 2.25 points or 0.41% from its previous closing of Rs. 551.70 on the BSE.
The scrip opened at Rs. 555.00 and has touched a high and low of Rs. 558.00 and Rs. 552.00 respectively. So far 6,022 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 612.00 on 12-Jul-2013 and a 52 week low of Rs. 386.50 on 05-Oct-2012.
Last one week high and low of the scrip stood at Rs. 575.00 and Rs. 543.10 respectively. The current market cap of the company is Rs.15, 008 crore.
The promoters holding in the company stood at 48.30% while Institutions and Non-Institutions held 40.97% and 10.73% respectively.
Glenmark Generics Inc, USA, the United States subsidiary of Glenmark Generics, has been granted Abbreviated New Drug Approval (ANDA) from United States Food and Drug Administration (US FDA) for Acamprosate Calcium Delayed Release Tablets, the generic version of forest Laboratories’ Camparl Delayed Release Tablets.
Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence. Based on IMS health sales data for the 12 month period during March 2013, Acamprosate garnered sales of $21 million.
Glenmark’s current portfolio consists of 88 products authorized for distribution in the U.S. marketplace and 53 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals and aims to be a global integrated generic and API leader.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1807.05 |
Dr. Reddys Lab | 1365.05 |
Cipla | 1475.10 |
Lupin | 2211.00 |
Zydus Lifesciences | 1004.60 |
View more.. |